Meret Gaugler, PhD, Joins Page Therapeutics Board of Directors
Page Therapeutics, a groundbreaking biotech dedicated to addressing metastatic cancer at its source, has recently welcomed Meret Gaugler, PhD, as an independent member of its Board of Directors. This strategic appointment reflects the company's commitment to advancing its innovative approaches in cancer therapy.
Background of Dr. Meret Gaugler
Dr. Gaugler brings a wealth of experience, combining her scientific background with over fourteen years as an investor in both public and private Life Sciences sectors. Presently, she holds a significant role as Partner-at-Large in Growth Investments at Novo Holdings, and she acts as a senior advisor on Life Sciences strategies for various organizations.
Comments from Leadership
Dr. Nicola Aceto, Professor of Molecular Oncology and scientific founder of Page Therapeutics, expressed enthusiasm about Dr. Gaugler's appointment. He stated, "Meret will provide invaluable strategic insights as we transition from an early-stage discovery company to a structured biotech. Our innovative strategy that targets the dissociation of circulating tumor cell clusters requires not only strict development processes but also long-term vision. Meret embodies both of these qualities."
Strategic Contributions to the Board
Joining Dr. Gaugler on the Board are key figures including Prof. Nicola Aceto, Prof. Christoph Rochlitz, MD, co-founder and Chief Medical Officer, as well as Daniele Scarinci, President and CEO. Together with Ciro Spedaliere, they represent financial investors who are pivotal in the current Seed round of financing.
Innovative Approach to Cancer Treatment
In her remarks, Dr. Gaugler highlighted Page Therapeutics' distinctive methodology in combating cancer. She noted, "Page's strategy for addressing cancer is not only insightful but also entirely novel. The preliminary evidence provided thus far is impressive. It is rare for a company at this developmental stage to have already generated a clinical proof of concept, attributed to Prof. Aceto's research utilizing a drug with a similar action to that of the company’s new therapeutics. Should their approach continue to yield anticipated results, we may set a new standard in cancer treatment."
About Page Therapeutics
Page Therapeutics AG is a preclinical-stage biotech company based in Switzerland, emerging from ETH Zurich and built upon the pioneering research of Prof. Nicola Aceto. The company focuses on the vulnerabilities of tumor cells circulating in the bloodstream, developing innovative therapies designed to disrupt cancer cell clusters, thus mitigating their potential to form metastases.
Frequently Asked Questions
What is the role of Meret Gaugler at Page Therapeutics?
Meret Gaugler has been appointed as an independent member of the Board of Directors, offering strategic insights for the company's development.
What experience does Dr. Gaugler bring to Page?
Dr. Gaugler has extensive experience in Life Sciences investments and currently acts as a Partner-at-Large for Novo Holdings.
Who are the other members of the Board of Directors at Page Therapeutics?
The Board includes Prof. Nicola Aceto, Prof. Christoph Rochlitz, MD, Daniele Scarinci, and Ciro Spedaliere, representing the financial investors involved in the Seed round.
What innovative approach does Page Therapeutics take towards cancer treatment?
Page Therapeutics aims to disrupt circulating tumor cell clusters, thereby inhibiting the formation of metastases, through novel therapeutic development.
Why is Dr. Gaugler's appointment significant for Page?
Her appointment is crucial as it brings in her unique perspective and experience in managing biotech growth and innovation, crucial for the company’s transition toward clinical trials.
